PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ocriplasmin - Vitreomacular traction

PAD Profile : Ocriplasmin - Vitreomacular traction

Brand Names Include :
Jetrea

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravitreal injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
12 October 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network recommends the use of ocriplasmin in line with NICE TA 297, as an option for treating vitreomacular traction in adults.

Ocriplasmin should be used only by specialists and as such is considered as RED on the traffic light system.

Ocriplasmin is excluded from the National Tariff when administered for its licensed indication. It should only be administered within a hospital setting by suitably trained specialists, and will not be transferred to primary care. Providers should apply for funding using the Blueteq system.

Associated BNF Codes

11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More